Tamarack Advisers’s Pacira BioSciences PCRX Stock Holding History

Tamarack Advisers’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,000	Closed	-$408K	–	41
2023 Q1	$408K	Sell	10,000 -90,000	-90%	-$3.58M	0.15%	36
2022 Q4	$3.86M	Sell	100,000 -95,000	-49%	-$4.62M	1.99%	17
2022 Q3	$10.4M	Buy	195,000 +20,000	+11%	+$1.11M	6.09%	3
2022 Q2	$10.2M	Sell	175,000 -30,000	-15%	-$1.97M	5.9%	4
2022 Q1	$15.6M	Sell	205,000 -35,000	-15%	-$2.33M	7.4%	2
2021 Q4	$14.4M	Sell	240,000 -135,000	-36%	-$7.44M	5.94%	2
2021 Q3	$21M	Buy	375,000 +15,000	+4%	+$865K	6.63%	4
2021 Q2	$21.8M	Sell	360,000 -190,000	-35%	-$12M	6.19%	4
2021 Q1	$38.5M	Sell	550,000 -185,000	-25%	-$13.2M	7.91%	1
2020 Q4	$43.6M	Buy	735,000 +80,000	+12%	+$4.68M	9.08%	1
2020 Q3	$39.4M	Sell	655,000 -45,000	-6%	-$2.61M	12.14%	1
2020 Q2	$36.7M	Buy	700,000 +150,000	+27%	+$6.27M	10.23%	1
2020 Q1	$18.4M	Sell	550,000 -72,500	-12%	-$3.01M	6.98%	6
2019 Q4	$27.8M	Sell	622,500 -152,500	-20%	-$6.48M	6.35%	5
2019 Q3	$29.5M	Buy	775,000 +150,000	+24%	+$5.99M	7.69%	4
2019 Q2	$27M	Buy	625,000 +305,000	+95%	+$12.9M	8.22%	4
2019 Q1	$12.2M	Buy	+320,000	New	+$12.5M	4.84%	8
2018 Q4	–	Sell	-150,000	Closed	-$7.37M	–	29
2018 Q3	$7.37M	Sell	150,000 -40,000	-21%	-$1.73M	2.11%	18
2018 Q2	$6.09M	Buy	190,000 +71,298	+60%	+$2.46M	2.04%	20
2018 Q1	$3.7M	Sell	118,702 -196,298	-62%	-$6.99M	1.76%	19
2017 Q4	$14.4M	Buy	315,000 +65,000	+26%	+$2.58M	7.85%	3
2017 Q3	$9.39M	Buy	250,000 +35,000	+16%	+$1.41M	5.75%	7
2017 Q2	$10.3M	Sell	215,000 -50,000	-19%	-$2.32M	5.99%	5
2017 Q1	$12.1M	Sell	265,000 -8,000	-3%	-$346K	7.55%	2
2016 Q4	$8.82M	Sell	273,000 -127,000	-32%	-$4.24M	6.24%	5
2016 Q3	$14.2M	Buy	400,000 +210,000	+111%	+$8.23M	4.46%	10
2016 Q2	$6.41M	Buy	+190,000	New	+$9.34M	2.46%	15

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Tamarack Advisers's PCRX Position: Q2 2023 in Review

Tamarack Advisers sold out of Pacira BioSciences (PCRX) in Q2 2023, closing a stake of 10,000 shares — an estimated $408K sold.

Tamarack Advisers first reported a position in PCRX in Q2 2016 and held it in 27 quarters. The position peaked at $43.6M in Q4 2020. 258 funds tracked by Wall St. Rank hold PCRX as of Q2 2023.

Tamarack Advisers reported no remaining Pacira BioSciences position as of Q2 2023 after selling out during the quarter.
Tamarack Advisers sold 10,000 Pacira BioSciences shares in Q2 2023, an estimated $408K.
Tamarack Advisers first reported a position in Pacira BioSciences in Q2 2016 and held it in 27 quarters.
Tamarack Advisers's Pacira BioSciences position peaked at $43.6M in Q4 2020.
258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2023.

Based on Tamarack Advisers's 13F filing for Q2 2023, filed 10 Aug 2023.